Charlevoix-Saguenay
Charlevoix Saguenay

Contact us
 
Return to database


We were unfortunately unable to download the information for this disease from OMIM.



Prevalence of clinical parameters (%)







Add new symptom/sign to this disease

Select symptom from list or write it in the box
Pubmed id number as a reference Organ system affected
Number of patients in the reference Percent affected patients (Between 0 and 1, eg. 0.1 = 10%)
Please provide your name and contact information as a reference
Name Institute Phone number Email address


List of symptoms



Symptom/sign Organ system Percent affected Pubmed id Added on(yyyy-mm-dd) Edit/add reference
Ataxia nervous 100 % 16961075 2012-02-14
Dysarthria nervous 100 % 16961075 2012-02-14
Nystagmus nervous 100 % 16961075 2012-02-14
Babinski's sign nervous 100 % 16961075 2012-02-14
Cerebellar atrophy nervous 100 % 16961075 2012-02-14
Neuropathy nervous 100 % 16961075 2012-02-14
Hyperactive reflexes nervous 75 % 16961075 2012-02-14
Spasticity nervous 75 % 16961075 2012-02-14
Pes cavus skeletal 75 % 16961075 2012-02-14
Finger deformity skeletal 63 % 16961075 2012-02-14
Retinal myelinated fibers nervous 63 % 16961075 2012-02-14



List of references:


Autosomal recessive spastic ataxia of Charlevoix-Saguenay.
Yoshihisa Takiyama,

Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) was originally found among the inhabitants of the Charlevoix-Saguenay region of Quebec, Canada. This disease is characterized by early-onset ataxia, spasticity, peripheral neuropathy, finger and foot deformities, and hypermyelination of the retinal nerve fibers. The mentality of the patients is usually intact. The principal neuropathology comprises atrophy of the upper vermis and the loss of Purkinje cells in the cerebellum. Although the lateral corticospinal tracts are degenerated, the precentral gyrus, dentate nucleus, and inferior olivary nucleus are intact. Recently, the gene responsible for ARSACS was determined to encode the sacsin protein in the Quebec patients. In 2004, we first reported a Japanese family with a SACS mutation. So far, we have identified the SACS mutations in a total of five Japanese families with ARSACS and analyzed the clinical features of eight patients. Interestingly, we found some atypical clinical features in the Japanese patients: a slightly later onset than that of the Quebec patients, an absence of myelinated retinal fibers, intellectual impairment, and a lack of spasticity. To date, there have been descriptions of non-Quebec patients with SACS mutations in Japan, Italy, Tunisia, and Turkey. Hereafter, as more SACS mutations are identified, the clinical spectrum of the "sacsinopathies" could expand.

Neuropathology : official journal of the Japanese Society of Neuropathology - Aug 2006